ConforMIS Priced, Nasdaq: CFMS

Sells fully customized knee replacement implants.

Industry: Health Care

Latest Trade: $5.45 +0.06 (+1.1%)

First Day Return: +28.3%

Return from IPO: -64.1%

Industry: Health Care

We are a medical technology company that uses our proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, which we refer to as customized, to fit each patient's unique anatomy. The worldwide market for joint replacement products is approximately $15 billion annually and growing, and we believe our iFit technology platform is applicable to all major joints in this market. We believe we are the only company offering a broad line of customized knee implants designed to restore the natural shape of a patient's knee. We have sold a total of more than 30,000 knee implants in the United States and Europe. In recent clinical studies, iTotal CR, our cruciate-retaining total knee replacement implant and best-selling product, demonstrated superior clinical outcomes, including better function and greater patient satisfaction compared to traditional, off-the-shelf implants. We recently initiated the limited launch of iTotal PS, our posterior-stabilized total knee replacement implant which addresses the largest segment of the knee replacement market. We expect to submit an application for clearance of iTotal Hip, our first customized hip replacement implant, with the FDA in 2015.
more less
IPO News for ConforMIS
more
IPO Data
IPO File Date 05/22/2015
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 9.0
Deal Size ($mm) $135
IPO Data
IPO Date 06/30/2015
Offer Price $15.00
Price Range $14.00 - $16.00
Offer Shares (mm) 9.0
Deal Size ($mm) $135
Underwriters
more
Company Data
Headquarters Bedford, MA
Founded 2004
Employees 353
Website www.conformis.com